Опубликована: Окт. 10, 2023
O Lúpus Eritematoso
Rheumatology International, Год журнала: 2023, Номер 43(8), С. 1381 - 1393
Опубликована: Май 24, 2023
Язык: Английский
Процитировано
32
Vaccines, Год журнала: 2025, Номер 13(2), С. 127 - 127
Опубликована: Янв. 27, 2025
Objective: To evaluate the humoral response to and impact of SARS-CoV-2 vaccination in patients with systemic lupus erythematosus a multicenter cohort design. Methods: Data for this analysis were obtained from Study Safety, Effectiveness Duration Immunity after Vaccination against Patients Immune-Mediated Inflammatory Diseases (SAFER), prospective, multicenter, phase IV, real-world study conducted across different regions Brazil June/2021 March/2024. aged >18 years (SLE) who received any one vaccines approved by Brazilian health regulatory agency (CoronaVac [inactivated vaccine], ChAdOx-1 [AstraZeneca], or BNT162b2 [Pfizer-BioNTech]) included. Immunogenicity was assessed pre- post-vaccination blood samples, monitored person remotely occurrence severity COVID-19. Results: Two hundred thirty-five SLE had completed their schedules (two doses + booster dose) included study. Most female (89.3%) low disease activity remission (72.4%); majority also on some form immunosuppressive therapy (58.1%). One sixteen two CoronaVac followed dose (Pfizer-BioNTech) vaccine, eighty-seven ChAdOx1-S (AstraZeneca) thirty-two three vaccine. Twenty-eight cases COVID-19, none meeting criteria severe recorded respiratory symptoms second Regarding immunogenicity, an increase seroconversion rate observed following consecutive vaccine doses, no difference between schedules, reaching 97.57% seropositivity dose. The geometric mean IgG titers differed first dose, being lowest CoronaVac-based schedule, but similar administration Conclusion: In SLE, are immunogenic, inducing robust response. No outcomes associated death hospitalization found evaluated patient sample. Complete including induced higher responses than incomplete especially initially immunized inactivated virus schedule those suboptimal
Язык: Английский
Процитировано
1
Medicina Clínica, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
International Journal of Rheumatic Diseases, Год журнала: 2025, Номер 28(1)
Опубликована: Янв. 1, 2025
Abstract Objective Since COVID‐19 infections are more common in systemic lupus erythematosus (SLE) patients, most recent research has focused on the outcome of COVID‐19, with fewer studies disease activity SLE. This aims to evaluate flares SLE infection while investigating predictive factors. Methods A questionnaire survey was conducted collect information patients previously diagnosed from multi‐center. infected after December 7, 2022, were selected. Detailed covering demographic characteristics, and clinical features, activity, medication collected through an electronic questionnaire. multivariate logistic regression model constructed factors for onset infection. Results total 240 finally included our analysis. Thirty (12.5%) those enrolled reported flare. Multivariate analysis models confirmed that active stage (OR 2.617, 95% CI 1.008–6.514, p = .041) duration 4.140, 1.412–11.694, .008) predictors flare Covid‐19 In contrast, immunosuppressants associated a low incidence 0.138, 0.042–0.46, .005). Conclusions The phase progression main risk exacerbation use immunosuppressive medications lower flare‐ups. These findings provide valuable insights managing during pandemic.
Язык: Английский
Процитировано
0
Lupus, Год журнала: 2025, Номер unknown
Опубликована: Фев. 27, 2025
To examine the clinical outcomes of systemic lupus erythematosus (SLE) patients with COVID-19 during Pre-Delta/Delta and Omicron periods. A retrospective study was conducted in a cohort adult Puerto Ricans SLE. Demographic parameters, SLE manifestations, comorbidities, pharmacologic treatment, exacerbations, hospitalizations, mortality were determined. SARS CoV-2 infection confirmed by polymerase chain reaction or antigen tests. Variables compared between Pre-delta/Delta Also, proportion cases to general population Rico. Of entire (n = 347), 169 (48.7%) had COVID-19. Twenty-two period 147 period. The significantly higher when Rico (25.7%), but no difference found. Overall, favorable, low rates flares (3.0%), hospitalizations (3.6%), (0.6%). Patients more likely have oral ulcers, anti-Smith antibodies, chronic kidney disease, whereas those symptoms (rhinorrhea, sore throat, cough). In summary, is this group SLE, high COVID-19, disease exacerbation, hospitalization, low. Few differences noted comparing
Язык: Английский
Процитировано
0
Vaccines, Год журнала: 2025, Номер 13(4), С. 396 - 396
Опубликована: Апрель 9, 2025
Background: In response to the SARS-CoV-2 pandemic, a massive vaccination campaign was launched. Nonetheless, concerns arose regarding some peculiar groups of patients, including those affected by Systemic Lupus Erythematosus (SLE), because immune-suppressive drugs routinely administered patients and risk possible disease flares. Since effects third booster in SLE have been poorly assessed, this study aims evaluate immunogenicity safety BNT162b2 vaccine dose, together with immunosuppressive drugs. Methods: A monocentric cohort age- sex-matched healthy controls (HCs) (all vaccinated three homologous doses) were consecutively enrolled 6 months (T1) after their shot. Vaccine evaluated analyzing humoral cellular immune responses at T1 12 (T2). assessing adverse events related (T0) comparing activity among T0, T1, T2. Effects assessed stratifying according therapy vaccination: (1) receiving (IS) or (2) not (Non-IS). Results: At comparable between HC subjects, while significantly higher (p = 0.01). No differences found T2 cohorts. Similarly, both T2, IS Non-IS comparable. Moreover, lupus flares limited mostly mild, no life-threatening reported. Conclusions: The is safe induces an response, which persistent ongoing
Язык: Английский
Процитировано
0
Open Access Rheumatology Research and Reviews, Год журнала: 2023, Номер Volume 15, С. 125 - 137
Опубликована: Июль 1, 2023
Abstract: Infections remain one of the leading causes death in systemic lupus erythematosus (SLE), despite awareness factors contributing to increased susceptibility infectious diseases SLE. Clinicians report challenges and barriers when encountering infection SLE as certain infections may mimic a flare. There are no evidence-based practice guidelines management fever SLE, with suboptimal implementations benefits related disease control and/or prevention strategies Vigilance identifying an opportunistic must be stressed confronted by diagnostic challenge during presentation febrile illness A balanced approach focus on reduction glucocorticoids dose, given need activity avoid organ damage mortality. Clinical judgement application biomarkers flares could reduce false positives overdiagnosis improve differentiation from flares. Further precision-based risk screening measures identify individuals who would benefit most low dose immunosuppressive therapy, targeted immune vaccination programs. Keywords: erythematosus, infections, challenges, management,
Язык: Английский
Процитировано
8
Biology, Год журнала: 2023, Номер 12(9), С. 1269 - 1269
Опубликована: Сен. 21, 2023
Multiple studies have reported new or exacerbated persistent resistant hypertension in patients previously infected with COVID-19. We used literature-based discovery to identify and prioritize multi-scalar explanatory biology that relates Cross-domain text mining of 33+ million PubMed articles within a comprehensive knowledge graph was performed using SemNet 2.0. Unsupervised rank aggregation determined which concepts were most relevant utilizing the normalized HeteSim score. A series simulations identified directly related COVID-19 connected via one three renin–angiotensin–aldosterone system hub nodes (mineralocorticoid receptor, epithelial sodium channel, angiotensin I receptor). The top-ranking relating included: cGMP-dependent protein kinase II, MAP3K1, haspin, ral guanine nucleotide exchange factor, N-(3-Oxododecanoyl)-L-homoserine lactone, aspartic endopeptidases, metabotropic glutamate receptors, choline-phosphate cytidylyltransferase, tyrosine phosphatase, tat genes, MAP3K10, uridine kinase, dicer enzyme, CMD1B, USP17L2, FLNA, exportin 5, somatotropin releasing hormone, beta-melanocyte stimulating pegylated leptin, beta-lipoprotein, corticotropin, growth hormone-releasing peptide 2, pro-opiomelanocortin, alpha-melanocyte prolactin, thyroid poly-beta-hydroxybutyrate depolymerase, CR 1392, BCR-ABL fusion gene, high density lipoprotein sphingomyelin, pregnancy-associated murine 1, recQ4 helicase, immunoglobulin heavy chain variable domain, aglycotransferrin, host cell factor C1, ATP6V0D1, imipramine demethylase, TRIM40, H3C2 COL1A1+COL1A2 QARS VPS54, TPM2, MPST, EXOSC2, ribosomal S10, TAP-144, gonadotropins, human gonadotropin hormone beta-lipotropin, octreotide, salmon calcitonin, des-n-octanoyl ghrelin, liraglutide, gastrins. Concepts mapped six physiological themes: altered endocrine function, 23.1%; inflammation cytokine storm, 21.3%; lipid metabolism atherosclerosis, 17.6%; sympathetic input blood pressure regulation, 16.7%; entry virus, 14.8%; unknown, 6.5%.
Язык: Английский
Процитировано
6
International Journal of Rheumatic Diseases, Год журнала: 2023, Номер 26(11), С. 2288 - 2293
Опубликована: Май 8, 2023
SARS-CoV2 primarily affects the respiratory system but a hyperinflammatory response leading to multisystem inflammatory syndrome - children (MIS-C), immune dysfunction and various autoimmune manifestations has also been noted. Autoimmunity depends on factors, including genetic predisposition, environmental dysregulation infections acting as triggers like Epstein-Barr virus, cytomegalovirus, human immunodeficiency hepatitis B. Molecular mimicry, bystander T-cell activation persistence of viral infection are main mechanisms behind these manifestations. We present here 3 cases newly diagnosed connective tissue disease with high titers COVID19 immunoglobulin G antibody in children. A 9-year-old girl fever, oliguria malar rash (prior history sore throat) 10-year-old fever for 2 weeks choreoathetoid movements were systemic lupus erythematosus (SLE) nephritis (stage 4) neuropsychiatric SLE, respectively per European League Against Rheumatism / American College Rheumatology 2019 criteria. An 8-year-old joint pain distress (a recent contact positive patient) presented altered sensorium, Raynaud's phenomenon noted, eventually mixed Kusukawa The immune-mediated post-COVID de-novo which necessitates further workup not many studies exist pediatric population.
Язык: Английский
Процитировано
5
Lupus Science & Medicine, Год журнала: 2024, Номер 11(2), С. e001131 - e001131
Опубликована: Июль 1, 2024
Objective To determine whether intercurrent infections are a risk factor for subsequent disease flares in systemic lupus erythematosus (SLE). Methods Demographic and clinical characteristics of 203 patients with SLE participating the Amsterdam cohort were collected at baseline during follow-up. Collection data on was registry-based categorised as minor or major, based predefined criteria. Proportional hazard models recurrent events time-varying covariates used to estimate HR flares. Results The incidence rates major 5.3 per 100 patient years 63.9 years, respectively. 3.6 15.1 flares, In proportional model, (major combined) associated occurrence combined; 1.9, 95% CI: 1.3 2.9). ratio flare following infection 7.4 (95% 2.2 24.6). Major not Conclusions results present study show that which supports hypothesis may trigger
Язык: Английский
Процитировано
1